Inflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Inflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophy
0.7 mg cohort showed a 54% lower mean rate of geographic atrophy (GA) growth (slope) than control eyes; a prespecified extrafoveal analysis showed an adjusted 4.0-letter mean BCVA advantage for K8 versus control – both statistically significant.NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics today announced positive Phase 2 results for its investigational drug K8 in GA. Over six more... The post Inflammasome Therapeutics Reports Positi…
Inflammasome Therapeutics Reports Positive Phase 2 Data for K8 in Geographic Atrophy
Key Takeaways K8 achieved a 54% reduction in geographic atrophy lesion growth at the 0.7-mg dose over 6 months and demonstrated a statistically significant 4.0-letter BCVA advantage in a prespecified subgroup analysis The phase 2 fellow-eye controlled trial enrolled 30 patients and reported no major safety concerns through 6 months, with no drug-related serious adverse events or intraocular inflammation Inflammasome Therapeutics plans to advan…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
